Applied Molecular Transport Appoints Holly Schachner, M.D. to its Board of Directors
24 Agosto 2021 - 3:01PM
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a
clinical-stage biopharmaceutical company, today announced the
appointment of Holly Schachner, M.D. a seasoned and accomplished
industry veteran to its Board of Directors.
“We are very excited to welcome Dr. Schachner to
AMT’s Board of Directors,” said Tahir Mahmood, Ph.D., chief
executive officer and co-founder of AMT. “Holly’s extensive
experience and expertise in late-stage global clinical development
and medical affairs across a broad range of therapeutic areas,
coupled with her strengths in organizational development, will be
invaluable as AMT prepares for the next stage of growth.”
Dr. Schachner added, “This is an exciting time
to join the AMT Board of Directors. The company’s unique platform
is opening new possibilities in mucosal immunology and in a wide
range of diseases with unmet need. I look forward to collaborating
with the AMT executive leadership team and my fellow board members
to further advance the company’s portfolio of potentially
transformational oral biologic therapeutics.”
Dr. Schachner currently serves as chief medical
officer of DoubleRainbow Biosciences, Inc. Prior to Double Rainbow,
Dr. Schachner was senior vice president and therapeutic head of
clinical science at MyoKardia, where she led a new therapeutic area
focused on diastolic dysfunction, myocardial inflammation, and
ischemia. Prior to joining MyoKardia, Dr. Schachner was chief
medical officer of specialty medicine at Allergan, where she led
the transformation to a matrixed medical organization and developed
innovative and global approaches to education and clinical trials.
Dr. Schachner’s career includes leadership roles as North America
medical head for the diabetes cardiovascular (DCV) business unit at
Sanofi, as well as serving simultaneously as U.S. medical chair.
Earlier in her career, Dr. Schachner held medical leadership
positions at Bayer Diabetes Care, Pfizer, Inc., and at Columbia
University.
Dr. Schachner holds a B.S. in Psychology from
the University of Michigan, an M.D. from Stony Brook School of
Medicine and completed a pediatric residency and pediatric
endocrinology fellowship at the Mount Sinai Medical Center in New
York.
About AMT-101AMT-101 is a novel
GI-selective, oral fusion of hIL-10 and AMT’s proprietary carrier
molecule, currently in development in four Phase 2 clinical trials
in inflammatory bowel diseases and rheumatoid arthritis. AMT-101 is
designed to cross the intestinal epithelial (IE) barrier with
limited entry into the bloodstream, thereby focusing hIL-10 at the
primary site of inflammation for UC and potentially avoiding the
side effects observed with systemic administration. By design,
AMT-101 is actively transported through the IE barrier into the GI
tissue, the primary site of inflammation in UC.
About AMT-126AMT-126 is a novel
GI-selective, oral fusion of hIL-22 and AMT’s proprietary carrier
molecule currently in development for diseases related to IE
barrier defects. IL-22 is a cytokine that repairs structural and
functional defects of the IE barrier and induces microbial defense.
AMT-126 is designed to act locally on the epithelial cells of the
intestinal tissue, thereby repairing the IE barrier and supporting
mucosal healing, potentially translating into clinically meaningful
improvements in a broad range of GI-focused, peripheral
inflammatory and other diseases.
About Applied Molecular Transport
Inc.Applied Molecular Transport Inc. is a clinical-stage
biopharmaceutical company leveraging its proprietary technology
platform to design and develop a pipeline of novel oral biologic
product candidates to treat autoimmune, inflammatory, metabolic,
and other diseases. AMT’s proprietary technology platform allows it
to exploit existing natural cellular trafficking pathways to
facilitate the active transport of diverse therapeutic modalities
across the intestinal epithelial (IE) barrier. Active transport is
an efficient mechanism that uses the cell’s own machinery to
transport materials across the IE barrier. AMT believes that its
ability to exploit this mechanism is a key differentiator of its
approach. AMT is developing additional oral biologic product
candidates in patient-friendly oral forms that are designed to
either target local intestinal tissue or enter systemic circulation
to precisely address the relevant biology of a disease.
AMT’s headquarters, internal GMP manufacturing
and lab facilities are located in South San Francisco, CA. For
additional information on AMT, please visit www.appliedmt.com
Forward-Looking StatementsThis
press release contains forward-looking statements as that term is
defined in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. Such forward-looking
statements involve substantial risks and uncertainties. All
statements other than statements of historical facts contained in
this press release are forward-looking statements including
statements relating to AMT’s plans, expectations, forecasts and
future events. Such forward-looking statements include, but are not
limited to, the potential of, and expectations regarding AMT’s
technology platform and AMT’s internal manufacturing capabilities,
statements regarding the optimization or expansion of our product
development plans or the design of future clinical trials,
statements regarding the potential of AMT-101 and AMT-126 or
regarding AMT-101 and AMT-126 clinical trials, including the timing
of data readouts from such trials and our ability to replicate past
clinical development strategies, statements regarding the potential
for AMT’s product candidates to treat or provide clinically
meaningful outcomes for certain medical conditions or diseases, and
assumptions regarding the biological mode of action of our product
candidates and the potential to avoid side effects with our product
candidates. In some cases, you can identify forward-looking
statements by terminology such as “believe,” “estimate,” “intend,”
“may,” “plan,” “potentially,” “will,” “expect,” “enable” or the
negative of these terms or other similar expressions. We have based
these forward-looking statements largely on our current
expectations and projections about future events and trends that we
believe may affect our financial condition, results of operations,
business strategy and financial needs. Actual events, trends or
results could differ materially from the plans, intentions and
expectations disclosed in these forward-looking statements based on
various factors. Information regarding the foregoing and additional
risks may be found in the section entitled “Risk Factors” in AMT’s
Annual and Quarterly Reports on Form 10-K and 10-Q filed with the
Securities and Exchange Commission (the “SEC”), and AMT’s future
reports to be filed with the SEC. These forward-looking statements
are made as of the date of this press release, and AMT assumes no
obligation to update the forward-looking statements, or to update
the reasons why actual results could differ from those projected in
the forward-looking statements, except as required by law.
Investor Relations Contact:Andrew ChangHead,
Investor Relations & Corporate
Communicationsachang@appliedmt.com
Media Contacts:Alexandra SantosWheelhouse Life
Science Advisorsasantos@wheelhouselsa.com
Aljanae ReynoldsWheelhouse Life Science
Advisorsareynolds@wheelhouselsa.com
Applied Molecular Transp... (NASDAQ:AMTI)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Applied Molecular Transp... (NASDAQ:AMTI)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024